drugset
drugset / Trial / NCT07269470

Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

NCT07269470 ↗

Phase 2 Not yet recruiting 40 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to find out if treatment with a combination of dasatinib plus ropeginterferon can help to control CML-CP. The safety of this combination will also be studied.

Timeline

Start
2026-11-01
Primary completion
2029-11-01
Completion
2029-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ropeginterferon alfa-2b Protein / enzyme biologic — Subcutaneous
Subject dasatinib anhydrous Small molecule — Oral

Indications

chronic myeloid leukemia